Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A new extra-judicial pathway for challenging pharmaceutical patents has intensified patent challenges and helped to clear the way for earlier generic entry.
The Supreme Court's decision in Sandoz v. Amgen introduces uncertainty into provisions that many viewed as necessary and enforceable, but its impact may ultimately be modest.
Examining the types of claim amendments that have transformed isolated gene claims from patent-ineligible into eligible subject matter provides clarity into the threshold of eligibility for gene-related patents.
Biotechnology and chemistry researchers look to the patent literature as a source of technical information more than researchers in other fields, and few researchers are deterred from reading patents by concerns about enhanced legal liability.
Despite the importance of patent landscape analyses in the commercialization process for life science and healthcare technologies, the quality of reporting for patent landscapes published in academic journals is inadequate.